Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results

PR Newswire May 4, 2017

Synthetic Biologics to Report First Quarter 2017 Operational Highlights and Financial Results on May 4, 2017

PR Newswire April 26, 2017

Research Reports Initiation on Biotech Stocks -- Sangamo, Eyegate Pharma, Synthetic Biologics, and Regulus

PR Newswire March 23, 2017

Synthetic Biologics to Present at the 29th Annual ROTH Conference

PR Newswire March 7, 2017

Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results

PR Newswire March 2, 2017

Synthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2, 2017

PR Newswire February 21, 2017

Technical Reports on Biotech Stocks -- Progenics Pharma, Intrexon, Synthetics Biologics, and 22nd Century

PR Newswire February 9, 2017

Synthetic Biologics to Present at the 2017 BIO CEO & Investor Conference

PR Newswire February 3, 2017

Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA

PR Newswire January 18, 2017

Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)

PR Newswire January 5, 2017

Synthetic Biologics to Present at the Biotech Showcase™ 2017 Conference

PR Newswire January 3, 2017

Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)

PR Newswire December 13, 2016

Synthetic Biologics Announces Participation in Two Upcoming Investor Conferences

PR Newswire December 1, 2016

Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants

PR Newswire November 18, 2016

Mid-Afternoon Market Update: NASDAQ Gains 1%; Stratasys Shares Drop Following Disappointing Results

Benzinga.com November 15, 2016

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com November 15, 2016

Mid-Day Market Update: Crude Oil Up Over 4%; Advance Auto Parts Shares Rise On Earnings Beat

Benzinga.com November 15, 2016

Mid-Morning Market Update: Markets Mixed; Home Depot Beats Q3 Expectations

Benzinga.com November 15, 2016

Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants

PR Newswire November 15, 2016

Synthetic Biologics Announces Commencement of Public Offering of Common Stock and Warrants

PR Newswire November 14, 2016